Trial Profile
Phase II Single-arm "Window-of-opportunity" Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 26 Nov 2021 Status changed from active, no longer recruiting to completed.
- 20 Jul 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 20 Jul 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.